Immunohistochemical detection of receptors, proteases, tumour suppressor proteins and proliferating markers as prognostic indicators for primary breast cancer patients;DER STELLENWERT DER IMMUNHISTOCHEMISCHEN BESTIMMUNG VON REZEPTOREN, GEWEBSPROTEASEN, TUMORSUPPRESSORPROTEINEN UND PROLIFERATIONSMARKERN ALS PROGNOSEINDIKATOREN BEIM PRIMAREN MAMMAKARZINOM

Geburtshilfe und Frauenheilkunde

Volumn 56, Issue 4, 1996, Pages 177-183

  Gohring U J ^a,b   Scharl, A ^a   Ahr, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; GROWTH HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEINASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UROKINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; RISK ASSESSMENT;

EID: 0029998407     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1022256     Document Type: Article

References (42)

1. th International Conference St. Gallen March 1-4 (1995) unpublished data.
2. Ahr, A., A. Scharl, U.-J. Göhring, G. Crombach, M. Stoffl: Immunhistochemischer Nachweis des pS2 Proteins an Paraffinschnitten von Mammakarzinomgeweben - Vergleich mit den Ergebnissen eines Immunradiometrischen Assays. Pathologe 16 (1995) 279-284.
3. Allred, D. G., G. M. Clark, R. Elledge, S. A. W. Fuqua, R. W. Brown, G. C. Chamness, C. K. Osborne, W. L. McGuire: Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer. J. Natl. Cancer Inst. 85 (1993) 200-206.
4. Beck, T., E. Weller, W. Weikel, C. Brumm, C. Wilkens, P.-G. Knapstein: Immunhistochemischer Nachweis und prognostische Bedeutung von p53 im Primärtumor von Mammakarzinompatientinnen. Geburtsh. u. Frauenheilk. 55 (1995) 252-257.
5. Beckmann, M. W., D. Niederacher, H. G. Schnurch, H. G. Bender: Die erbB-Gen-Familie: Bedeutung für die Tumorentwicklung, Prognose und für neue Therapiemodalitäten. Geburtsh. u. Frauenheilk. 53 (1993) 742-753.
6. Beckmann, M. W., B. Tutschek, U.-J. Göhring, K. Engels, F. K. Picard, A. Scharl, D. Niederacher, H. G. Schnürch: Immunhistochemischer Nachweis des "epidermal growth factor receptor (EGF-R)" an Paraffinschnitten von Mammakarzinomgeweben: Korrelation und klinische Wertigkeit Geburtsh. u. Frauenheilk. 55 (1995) 258-265.
7. rd, I. F. Mizukami, D. A. Lawrence, B. M. Ljung, M. A. Shuman, H. S. Smith: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54 (1994) 861-866.
8. Cox, D. R.: Regression models and life-tables. J. R. Stat. Soc. [B] 34 (1972) 187-200.
9. Duffy, M. J., P. O'Grady, D. Devany, L. O'Siorain, J. J. Fennelly, H. J. Lijnen: Urokinase-plasminogen activator, a marker for aggressive breast cancer. Preliminary report. Cancer 62 (1988) 531-533.
10. Duffy, M. J., D. Reilly, E. McDermott, N. O'Higgins, J. J. Fennelly, P. A. Andreasen: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74 (1994) 2276-2280.
11. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339 (1992) 71-85.
12. Fellbaum, C., F. Jänicke, M. Schmitt, L. Hoeppner, M. Kramer, W. Gössner, H. Graeff, H. Höfler: Plasminogen-Aktivator vom Urokinase-Typ bei Mammakarzinomen: Korrelation zwischen biochemischer und immunhistochemischer Bestimmung? Verh. Dtsch. Ges. Path.74 (1990) 453.
13. Fisher, E. R., S. Anderson, C. Redmond, B. Fisher: Pathologic Findings from the National Surgical Adjuvant Breast Project Protocol B-06. Cancer 71 (1993) 2507-2514.
14. Foekens, J. A., W. L. J. van Putten, H. Portengen, H. Y. W. C. M. de Koning, H. Y. W. C. M. B. Thirion, J. Alexieva-Figusch, J. G. M. Klijn: Prognostic value of pS2 and Cathepsin D in 710 human primary breast cancer tumors: multivariante analysis. J. Clin. Oncol. 11 (1993) 899-908.
15. Fox, B. S., K. Smith, J. Hollyer, M. Greenall, D. Hastrich, A. L. Harris: The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 29 (1994) 41-49.
16. Glick, J. H., R. D. Gelber, A. Goldhirsch, H.-J. Senn: Adjuvant therapy of primary breast cancer: closing summary. In Senn, H.-J., R. D. Gelber, A. Goldhirsch, B. Thürlimann (eds.): Adjuvant therapy in breast cancer. Recent Results in Cancer Research. Springer, Berlin, Heidelberg, London (1993) 291-300.
17. Göhring, U.-J., Y. Aslan-Schadwinkel, A. Scharl: Die Expression des p185neu-Onkoproteins markiert eine ungünstige Prognose bei kleinen, nodal-negativen, nicht adjuvant systemisch behandelten Mammakarzinomen (T1 N0). Geburtsh. u. Frauenheilk. 53 (1993) 625-629.
18. Göhring, U.-J., A. Scharl, U. Thelen, A. Ahr, G. Crombach: Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. J. Clin. Pathol. (1995) in press.
19. Göhring, U.-J., A. Scharl, M. Stoffl, A. Ahr, M. Becker, G. Crombach: Der Nachweis des Proliferating Cell Nuclear Antigen (PCNA) im primären Mammakarzinom - ein Proliferationsmarker als Prognosefaktor bei nodal-positiven Patientinnen. TumorDiagnostik und Therapie 15 (1994) 171-175.
20. Göhring, U.-J., A. Ahr, A. Scharl, V. Weisner, W. Neuhaus, G. Crombach, J. A. Holt: Immunohistochemical detection of epidermal growth factor receptor (EGF-R) lacks prognostic significance for breast carcinoma. J. Soc. Gynecol. Invest. 2 (1995) 653-659.
21. Göhring, U.-J., A. Scharl, Ch. Heckel, G. Crombach: P53 protein in primary breast carcinoma - immunohistochemical detection and clinical value as prognostic factor. Archives of Gyn. Obst. 256 (1995) 139-146.
22. Jänicke, F. et al.: Prognosefaktoren beim primären Mammakarzinom. In Sauer, H. (ed.): Mammakarzinome. Schriftenreihe Tumorzentrum München (5. Auflage) (1994) 5-10, 37-49.
23. Jänicke, F., M. Schnitt, L. Pache, K. Ulm, N. Harbeck, H. Hofler, H. Graeff: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. 24 (1993) 195-208.
24. Joensuu, H., S. Toikkanen, J. Isola: Stromal cell cathepsin D expression and long-term survival in breast cancer. Br. J. Cancer 71 (1995) 155-159.
25. Klijn, J. G. M., P. M. J. J. Berns, P. I. M. Schmitz, J. A. Foekens: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev. 13 (1992) 3-17.
26. Lipponen, P., S. Aaltomaa, S. Syrjanen, K. Syrianen: P53 protein expression in breast cancer is related to histopathological characteristics and prognosis. Int. J. Cancer 55 (1993) 51-56.
27. Mansour, E. G., P. M. Ravdin, L. Dressler: Prognostic factor in early breast cancer carcinoma. Cancer 74 (1994) 381-400.
28. McGuire, W. L., A. K. Tandon, D. C. Allred, G. C. Chamness, G. M. Clark: How to use prognostic factors in axillary node-negative breast cancer patients. J. Natl. Cancer Inst. 82 (1990) 1006-1015.
29. McGuire, W. L.: Breast cancer prognostic factors: Evaluation guidelines. J. Natl. Cancer Institute 83 (1991) 154-155.
30. Peto, R., M. C. Pike, P. Armitage: Design and analyses of randomised clinical trials requiring prolonged observation of each patients. Br. J. Cancer 35 (1977) 1-39.
31. Poller, D. N., C. E. Hutchings, M. Galea, J. A. Bell, R. A. Nicholson, C. W. Elston, R. W. Blamery, I. O. Ellis: P53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br. J. Cancer 66 (1992) 583-588.
32. Prioleau, J., S. J. Schnitt: p53 Antigen loss in stored paraffin slides. New Engl. J. Med. 332/22 (1995) 1521-1522.
33. Ravdin, P. M., A. K. Tandon, D. C. Allred, G. M. Clark, S. A. Fuqua, S. H. Hilsenbeck, G. C. Chamness, C. K. Osborne: Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J. Clin. Oncol. 12 (1994) 467-474.
34. Remmele, W., H. E. Stegner: Vorschlag zur einheitlichen Definition eines Immunreaktiven Scores (IRS) für den immunhistochemischen Rezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8 (1987) 811-814.
35. Remmele, W., J. Sauer-Manthey: Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch. A. Pathol. Anat. Histopathol. 422, 6 (1993) 467-473.
36. Sainsbury, J. R. C., J. R. Farndon, G. K. Needham, A. J. Malcolm, A. L. Harris: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 1398-1402.
37. Scharl, A., M. Vierbuchen, H. Würz: Immunhistochemischer Nachweis von Östrogen- und Progesteronrezeptoren beim Mammakarzinom mit Hilfe monoklonaler Antikörper: Vergleich mit der biochemischen Rezeptoranalyse. Pathologe 10 (1989) 31-38.
38. Schönborn, I., C. Minguillon, M. Möhner, K. Ebeling: Die Bedeutung der PCNA-Proliferationsfraktion und histomorphologischer Prognosefaktoren für das Überleben beim Mammakarzinom. Pathologe 14 (1993) 307-a312.
39. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, W. L. McGuire: Human breast cancer: Correlation of relapse and survival with amplification of Her-2/neu oncogene. Science 235 (1987) 177-182.
40. Stonelake, P. S., P. G. Baker, W. M. Gillespie, J. A. Dunn, D. Spooner, J. M. Morrison, N. J. Hundred, G. D. Oates, M. J. Lee, J. P. Neoptolemos: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur. J. Cancer 30 A, 1 (1994) 5-11.
41. Tandon, A. K., G. M. Clark, G. C. Chamnes, J. M. Chirgwin, W. L. McGuire: Cathepsin D and prognosis in breast cancer. N. Engl. J. Med. 322 (1990) 297-302.
42. Tetu, B., J. Brisson, C. Còté, S. Brisson, D. Potvin, N. Roberge: Prognostic significance of Cathepsin-D Expression in Node-Positive Breast carcinoma: an immunohistochemical Study. Int. J. Cancer 55 (1993) 429-435.